千红制药
(002550)
| 流通市值：97.42亿 | | | 总市值：132.46亿 |
| 流通股本：9.41亿 | | | 总股本：12.80亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 861,771,495.13 | 450,880,337.41 | 1,526,242,786.73 | 1,207,602,942.05 |
| 营业收入 | 861,771,495.13 | 450,880,337.41 | 1,526,242,786.73 | 1,207,602,942.05 |
| 二、营业总成本 | 638,132,988.95 | 326,264,437.3 | 1,232,752,211.68 | 957,440,753.08 |
| 营业成本 | 376,487,293.53 | 205,621,561.35 | 689,067,135.85 | 555,283,016.54 |
| 税金及附加 | 11,088,492.94 | 5,400,824.59 | 23,708,113.5 | 19,118,814.27 |
| 销售费用 | 150,421,861.82 | 72,835,202.57 | 304,542,485.82 | 237,447,737.71 |
| 管理费用 | 59,076,563.83 | 27,546,374.25 | 123,178,747.88 | 85,931,181.56 |
| 研发费用 | 43,847,841.22 | 16,394,484.79 | 104,447,205.97 | 60,923,369.71 |
| 财务费用 | -2,789,064.39 | -1,534,010.25 | -12,191,477.34 | -1,263,366.71 |
| 其中:利息费用 | 181,499.97 | 181,499.97 | 1,386,462.46 | 1,172,924.53 |
| 其中:利息收入 | 5,342,649.84 | 2,406,920.38 | 9,961,075.25 | 5,969,694.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,768,482.85 | 1,545,269.49 | 2,359,456.78 | 1,280,070.99 |
| 加:投资收益 | 5,025,058.69 | 2,351,401.7 | 11,529,730.94 | 5,156,866.58 |
| 资产减值损失(新) | - | - | -3,092,271.82 | 49,648.14 |
| 信用减值损失(新) | 51,995,351.1 | 52,615,441.74 | 78,918,449.99 | 81,940,746.89 |
| 其他收益 | 9,897,157.03 | 5,903,794.72 | 13,182,534.27 | 8,382,086.13 |
| 四、营业利润 | 293,324,555.85 | 187,031,807.76 | 396,388,475.21 | 346,971,607.7 |
| 加:营业外收入 | 16,303 | 14,384.28 | 1,131,545.89 | 1,347,442.09 |
| 减:营业外支出 | 240,819.26 | 11,073.04 | 1,681,046.39 | 619,459.23 |
| 五、利润总额 | 293,100,039.59 | 187,035,119 | 395,838,974.71 | 347,699,590.56 |
| 减:所得税费用 | 43,517,864.41 | 29,425,931.63 | 62,656,427.89 | 49,101,668.66 |
| 六、净利润 | 249,582,175.18 | 157,609,187.37 | 333,182,546.82 | 298,597,921.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 249,582,175.18 | 157,609,187.37 | 333,182,546.82 | 298,597,921.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 258,050,517.71 | 160,968,397.92 | 356,032,007.44 | 309,585,156.72 |
| 少数股东损益 | -8,468,342.53 | -3,359,210.55 | -22,849,460.62 | -10,987,234.82 |
| 扣除非经常损益后的净利润 | 198,685,959.45 | 106,923,165.21 | 268,999,200.65 | 228,237,014.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.13 | 0.28 | 0.25 |
| (二)稀释每股收益 | 0.21 | 0.13 | 0.28 | 0.25 |
| 八、其他综合收益 | 207,912.65 | 97,808.99 | -2,774,232.01 | 139,702.95 |
| 归属于母公司股东的其他综合收益 | 207,912.65 | 97,808.99 | -2,774,232.01 | 139,702.95 |
| 九、综合收益总额 | 249,790,087.83 | 157,706,996.36 | 330,408,314.81 | 298,737,624.85 |
| 归属于母公司股东的综合收益总额 | 258,258,430.36 | 161,066,206.91 | 353,257,775.43 | 309,724,859.67 |
| 归属于少数股东的综合收益总额 | -8,468,342.53 | -3,359,210.55 | -22,849,460.62 | -10,987,234.82 |
| 公告日期 | 2025-08-23 | 2025-04-19 | 2025-04-19 | 2024-10-18 |
| 审计意见(境内) | | | 标准无保留意见 | |